๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Nonprofit model for drug discovery and development

โœ Scribed by Gregory Daniel Frank; Ling Jong; Nathan Collins; Edward G. Spack


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
521 KB
Volume
68
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Drug discovery and development, Vol. 1:
โœ Robert H. Glew ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› The American Society for Biochemistry and Molecula ๐ŸŒ English โš– 25 KB ๐Ÿ‘ 1 views

Drug Discovery and Development, edited by M.S. Chorghade, is a two volume set, the first of which is now available. Volume 1, Drug Discovery, is composed of 16 chapters by authors who are active in the field of medicinal chemistry and are able to bring historical perspective to this important field

Adaptivity in drug discovery and develop
โœ Frank Bretz; Michael Branson; Carl-Fredrik Burman; Christy Chuang-Stein; Christo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 219 KB ๐Ÿ‘ 1 views

## Abstract The development of novel drugs is becoming increasingly challenging, inefficient, and costly, as acknowledged by all major stakeholders of pharmaceutical products. Adaptive designs have attracted considerable attention in recent years, as they promise an increase in efficiency of the dr

Introduction to Chemical Proteomics for
โœ Sung-Young Han; Seong Hwan Kim ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 838 KB

## Abstract A fundamental goal of chemical proteomics is to identify target proteins for bioactive small molecules and then apply them to drug discovery and development as valid and drugable targets. Here, we introduce integrated technologies for the rapid identification of target proteins, methodo

Role of drug metabolism in drug discover
โœ Gondi N. Kumar; Sekhar Surapaneni ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 300 KB ๐Ÿ‘ 1 views

## Abstract Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. High metabolic lability usually leads to poor bioavailability and high clearance. Formation of active or toxic metabolites will have an impact on the pharmacological and t